Among young patients with inflammatory bowel disease, most whom were positive for SARs-CoV-2, had a non-neutralizing antibody, according to data presented at Digestive Disease Week.

“Rapid decline in antibody levels following SARs-CoV-2 infection in our IBD patients treated with biologics suggests greater risk for reinfection, especially for variants that can escape the antibodies,” Joelynn Dailey, DO, from Connecticut Children’s Medical Center, Hartford, said during her presentation.

Dailey and colleagues collected serum from 426 young patients with IBD at the time of infusion with

Full Article: